

EFFICACY OF PHOSPHOMYCIN IN THE CONTROL OF *E. COLI* INFECTION IN BROILERS

Adayel, S. A. and Seham Malahat

Dept. of Biochemistry, Nutrition and Toxicology,

Animal Health Research Institute (Zagazig Branch)

ABSTRACT

Ca fosfomycin is active against wide range of bacteria e.g. E. coli, Staphylococci and Streptococci. The present work was carried out to evaluate the antibacterial effect of Ca fosfomycin in healthy and experimentally infected broilers with E. coli. The effect of therapeutic dose of ca.fosfomycin (40 mg/kg B.Wt) in drinking water for 3-5 successive days on healthy and experimentally infected broilers, with E. coli was determined. The minimal inhibitory concentration (MIC) of fosfomycin against tested E. coli was 0.5 ug/ml. In vivo studies were carried out on 200 broiler chickens. They were divided into 4 equal groups: Group 1 served as healthy control (non infected, non treated), the other 3 groups were infected with 0.25ml of broth containing $10^{3.3}$ C.F.U E. coli at age of 20 days. Group 2 remained infected, non treated. Group 3 and 4 were treated orally with Ca fosfomycin 40 mg/kg b.wt. for 3 and 5 successive days respectively. Treatment starts twenty four hours post infection. At the age of 2 and 3 weeks post-infection, the obtained results concerning clinical signs, mortality rate, re-isolation of E. coli and the body weight gain showed that Ca fosfomycin (40 mg/kg) for 3 and 5 successive days was highly effective agent in the control of experimental infection.

Moreover, serum AST, ALT, uric acid, blood urea nitrogen and leucocytic count were significantly increased in chicken infected with E. coli while serum total protein and albumin were significantly decreased. These parameters were improved toward to the normal levels in chicks infected with E. coli and treated with fosfomycin for 3 and 5 successive days.

INTRODUCTION

Antibiotics are widely used in veterinary medicine to overcome many bacterial infection in poultry farms. Fosfomycin is one of broad spectrum bactericidal antibiotic, which is useful in treatment of *E. coli* infection in poultry farms.

E. coli infections in chicken's farms are considered as one of the most serious problem, affecting poultry industry (Curtis et al., 1970).

Ca fosfomycin is the newest generation in fosfonic acid derivatives (potassium fosfomycin and disodium fosfomycin) developed totally for poultry use and medication by Bedson-SA over 15 years of continuous research and development.

Fosfomycin is a broad spectrum antibiotic produced by *Streptomyces jadaviae* strain (Christensen et al., 1969). It's a derivative of fosfonic acid, unrelated to other antibiotic groups, its molecule is very small containing only two carbon elements in its structure, this allow its greater permeability in area of abscesses and poor vascularization (Ishizawa and Cole, 1987).

The bactericidal effect of fosfomycin is due to inhibition of the first step in peptidoglycan synthesis among processes of cell wall biosynthesis in bacteria, incorporating it self into the organism by an active transport system. It's active against both Gram-positive and Gram-negative organisms (Perea et al., 1977).

This study was planned to study the activity of Ca fosfomycin against isolates of *E. coli* spp. in vitro and vivo. Also to investigate the optimum effective dose and duration of therapy for control spp. of *E. coli* as well as its effect on body weight gain and some liver and kidney functions.

MATERIAL AND METHODS

Material:

(1) Drug:

Ca fosfomycin (Adwia Co.).

(2) Microorganism: pathogenic *E. coli* serotype O78, obtained from Hamada Lab.

Media:

MacConky's agar, Nutrient agar, MacConky's broth (Oxoid) and Nutrient broth (Cruickshank et al., 1971).

(3) Experimental chicks:

Two hundred apparently healthy one day old, baby chicks (Cup breed), were used in the present study. They were obtained from a poultry farm in Sharkia Governorate.

Methods:

Antibacterial effects:

(A) Antibacterial activity in vitro:

- (1) Determination of minimum inhibitory concentration (MIC) using broth dilution method for fosfomycin according to **Cruickshank et al., (1975)**.
- (2) Sensitivity test of *E. coli* to fosfomycin in comparison with other antimicrobial agents was studied in vitro using disc diffusion method according to **Backer et al., (1980)**.

(B) Antibacterial activity in vivo:

Experimental evaluation of fosfomycin:

Two hundred and twenty days old broiler chicks were used. Five chicks were randomly sacrificed and bacteriologically examined to confirm that free from *E. coli*. Chickens were divided into 4 equal groups, each of five. Group 1 chicks (non infected non treated) where 2nd group was infected with *E. coli* and remained non treated (positive control). The 3rd and 4th groups were infected with *E. coli* and treated with fosfomycin at a dose level of 40 mg/kg b.wt. orally for 3 and 5 successive days respectively. Infection was done at the 20 days of age with *E. coli* (0.78 strain by intramuscular injection of 0.75 ml of $10^{3.3}$ C.F.U (**Badr, 2003**).

Treatment started 24 hrs post infection, the period of experiment lasted to the age of 6 weeks. All chicks were weighted; mortality rate, clinical symptoms and PM lesions were recorded for all groups at the end of the experiment. Blood samples were obtained and sera were collected.

(C) Haematological studies:

Blood samples were collected from each chicken at the 3rd, 7th and 21 days post treatment in all groups. Blood samples were collected in 2 tubes; one without anticoagulant for separation of serum. The collected serum samples were used for estimation of AST, ALT (**Reitman and Frankel, 1957**), total proteins (**Welchselbaum, 1946**), albumin (**Doumas et al., 1981**) and uric acid & blood urea (**Trinder, 1969**).

The other tube with EDTA as anticoagulant for erythrocytic and total leukocytic counts (**Natt and Herrick, 1952**) and packed cell volume was determined using the micro haematocrit method (**Cohen, 1967**).

Statistical analysis:

Statistical analysis was carried out according to **Snedecor and Cochran, (1982)**.

RESULTS

Results of antibiogram study revealed that fosfomycin, pefloxacin, kanamycin and ciprofloxacin were the most effective antimicrobials against *E. coli* (Table 1). The MIC of fosfomycin against *E. coli* was 0.5 ug/ml.

Experimentally infected chicks with *E. coli* O₇₈ showed clinical signs manifested by depression, loss of appetite, drooping of wings, diarrhea and respiratory symptoms. Post mortem examination of dead infected chicks as in Table (2). Oral administration of Ca fosfomycin at a dose of 40 mg/kg b.wt. for 3 and 5 successive days induced a significant ($P > 0.05$) increase of body weight gain in comparison to infected non-treated group (Table 3).

The effect on erythrocytic count, PCV, haemoglobin concentration and leucocytic count was shown in Table (4). Alteration of serum biochemical values in all groups was detected. Infected chicks with *E. coli* denoted significant increase in activities of AST, ALT, uric acid and urea but decreased significantly compared with control group.

These parameters were revealed to nearly normal level in infected treated chicks with fosfomycin (Tables 5 and 6).

DISCUSSION

Avian *E. coli* infection is a problem of economic concern to all phases of the poultry industry (Culnak et al., 1991).

Antibiogram of *E. coli* O₇₈ to ca fosfomycin and other commonly used antimicrobials was performed. The results obtained indicated that *E. coli* was highly sensitive to ca fosfomycin. These results are in similar to previously cited results (Goto et al., 1981), they reported that *E. coli* showed sensitivity to ca fosfomycin. Also, other numbers of quinolone groups are still effective in inhibiting *E. coli* infection (Fernandez et al., 1998).

In addition, the MIC of ca fosfomycin was determined as 0.5 ug/ml as reported by Marchese et al., (2003).

The clinical signs observed on the infected and non-treated chicks were depression, loss of appetite respiratory manifestations and loss of body weight. Similar symptoms, were previously recorded (Awaad, 1972). The treatment of infected chicks with Ca fosfomycin at dose 40 mg/kg b.wt for 3 and 5 successive days reduced clinical signs and decreased mortality rate from 50% to 15% and 5% respectively. Numerous reports have been indicated the effectiveness of Ca fosfomycin in the treatment of *E. coli* infection (Laurance et al., 1997).

The obtained results revealed that administration of Ca fosfomycin at a dose level of 40 mg/kg b.wt for 3 and 5 successive days to infected chicks as well as healthy non infected chicks (control group) showed no significant variation in body weight gain. On contrary infected non treated chicks had loss body weight gain when compared with control and infected treated groups.

The decrease in the body weight post infection may be attributed to the deleterious effect of microorganism which invade the host and retarded its metabolic activity (Annani, 1993). On other hand the body gain of chicks infected with *E. coli* was increased after treatment with Ca fosfomycin in compared to infected non-treated (Mckellar and Varma, 1996). The improvement of body weight gain in infected and treated chicks might be attributed to bactericidal effect of the drug on the infection and consequently improved general health condition (Fernandez et al., 1998). These results provide a farther reason for efficacy of Ca fosfomycin in control *E. coli* infection. In present investigation, it has been shown that Ca fosfomycin administration in therapeutic dose in infected chickens results in non-significant changes in erythrocytic count and packed cell volume, where as leucocytic count was significantly increased. Our results coincide with that obtained by Mckellar and Varma (1996).

Biochemical analysis of serum from chicks infected with *E. coli* showed that serum AST, ALT were significantly ($P > 0.05$) increased. These parameters were improved towards the normal levels as result of treatment of infected chickens with Ca fosfomycin.

The increase in serum AST and ALT after infection indicating a hepatocellular damage (Doxey, 1971). Treatment with Ca fosfomycin at level of 40 mg b.wt for 3 and 5 successive days displayed non-significant changes in serum AST, ALT as well as total proteins and albumin. Recent investigation recorded similar results (All and Youssef, 2003). Our results agree with those obtained by All et al., (2003).

Uric acid and blood urea levels were significantly increased in infected non-treated chicks with *E. coli*, this finding was agreed with the results obtained by Mckellar and Varma (1996). Our results revealed that there were non significant changes in uric acid and blood urea levels in infected and treated group. These results coincide with Halliwell (1981) who reported that Ca fosfomycine had no significant nephrotoxicity in rats.

Finally it could be concluded that the treatment of *E. coli* infection in broiler chicks with Ca fosfomycin at dose of 40m/kg b.wt for 5 successive days has superior activity and efficiency than its administration for 3 successive days.

Table (1): Sensitivity test for some types of antibiotics against the used *E. coli* organism.

Antibacterial	Disc concentration (μg)	Zone of inhibition (mm)
Fosfomycin	15	17
Erythromycin	30	18
Oxytetracyclin	30	24
Gentamycin	10	16
Ciprofloxacin	5	12
Colistin	25	15

Table (2): Effect of Ca. Fosfomycin (40 mg/kg) on the mortality rate (%) and lesion scores of non-infected and *E. coli* experimentally infected chickens (Mean \pm SE) (n= 5).

Groups	Mortality %	Air sacculitis %	Pericarditis	Perihepatitis	Ascitis	Enteritis	Reisolation
Non-infected, non-treated	0	0	0	0	0	0	0%
Infected, non-treated	15	70	50	75	40	35	100%
Infected, treated with Ca fosfomycin (40 mg/kg) for 3 successive days.	5	20	15	5	3	8	10%
Infected, treated with Ca fosfomycin (40 mg/kg) for 5 successive days.	2	12	8	3	0	2	5%

Table (3): The effect of Ca. fosfomycin (40 mg/kg) in drinking water for 3-5 successive days on the body weight (gm) in healthy and experimentally infected chickens with *E. coli* (Mean \pm SE) (n=5).

Groups	Body weight (gm) time post infection			
	3 rd day	7 th day	14 th day	21 st day
Non-infected, non-treated	740 \pm 40	1128 \pm 80	1680 \pm 210 [*]	2030 \pm 305 [*]
Infected, non-treated	662 \pm 54	920 \pm 511	1398 \pm 1452 ^{***}	1680 \pm 442 ^{***}
Infected, treated with Ca fosfomycin (40 mg/kg) for 3 successive days.	721 \pm 25	994 \pm 224	1582 \pm 219 [*]	1822 \pm 155 [*]
Infected, treated with Ca fosfomycin (40 mg/kg) for 5 successive days.	718 \pm 32	1062 \pm 32	1570 \pm 374 [*]	1922 \pm 301 ^{**}

*P > 0.05

**P > 0.01

***P > 0.001

Table (4): Effect of Ca fosfomycin (40 mg/kg) in drinking water for 3-5 successive days on erythrocytic counts (10^6 UL), packed cell volume (%) and leukocytic counts (10^3 UL) in healthy and experimentally infected broilers with *E. coli* (mean \pm SE) (n=5).

Groups	Red blood corpuscles (10^6 UL) time post infection (days)			Packed cell volume (P.C.V.) (%) time post infection (days)			Leukocytic count (10^3 UL) time post infection (days)		
	3 rd day	7 th day	21 st day	3 rd days	7 th days	21 st days	3 rd days	7 th days	21 st days
Non-infected, non-treated	2.98 \pm 0.08	3.21 \pm 0.12	3.12 \pm 0.14	32.61 \pm 0.08	32.15 \pm 1.2	34 \pm 0.83	14.5** \pm 1.5	15.8*** \pm 0.88	15.8*** \pm 1.2
Infected, non-treated	2.87 \pm 0.05	2.5*** \pm 0.07	2.06*** \pm 0.06	24.22*** \pm 0.1	23.8** \pm 1.2	26.4** \pm 0.55	17.4 \pm 1.1	19.4 \pm 0.55	20.6 \pm 1.2
Infected, treated with Ca fosfomycin for 3 successive days	2.79 \pm 0.04	2.85** \pm 0.07	2.83* \pm 0.14	32.1 \pm 0.41	30.12 \pm 1.2	32.4 \pm 0.9	13.5** \pm 0.22	17.5 \pm 0.43	15.5*** \pm 1.3
Infected, treated with Ca fosfomycin for 5 successive days	2.85 \pm 0.08	2.92* \pm 0.06	2.99* \pm 0.07	32.2 \pm 0.12	32.2 \pm 0.2	33.2 \pm 0.68	13.8** \pm 0.18	16.8** \pm 0.44	15.8*** \pm 0.54

**P > 0.01

**P > 0.01

***P > 0.001

Table (5): Effect of Ca fosfomycin (40 mg/kg) in drinking water for 3-5 successive days on total serum proteins and albumin (gm/dl) of non-infected and *E. coli* experimentally infected chickens (mean \pm SE) (n=5).

Groups	Total serum protein (gm/dl)			Albumin (gm/dl)		
	Time post infection (days)			Tim post infection (days)		
	3 rd day	7 th day	21 st day	3 rd days	7 th days	21 th days
Non-infected, non-treated	3.1 \pm 0.42	3.7 \pm 0.44	4.2 \pm 0.22	1.71 \pm 0.18	2.12 \pm 0.12	2.17 \pm 0.08
Infected, non-treated	2.7* \pm 0.34	2.5* \pm 0.11	2.9* \pm 0.18	1.2* \pm 0.11	1.8* \pm 0.12	1.6* \pm 0.03
Infected, treated with Ca fosfomycin for 3 successive days	4. \pm 0.12	4.2 \pm 0.12	3.8 \pm 0.23	1.7 \pm 0.24	1.9 \pm 0.11	2.1 \pm 0.03
Infected, treated with Ca fosfomycin for 5 successive days	4.2 \pm 0.17	4.1 \pm 0.34	4.3 \pm 0.24	1.6 \pm 0.26	1.87 \pm 0.03	2.2 \pm 0.02

*P > 0.05

Table (6): Effect of Ca-fosfomycin (40 mg/kg) in drinking water for 3-5 successive days on blood urea, uric acid, alanine amino transferase (AST & ALT) and alkaline phosphatase in healthy and experimentally infected broilers with *E. coli* (Mean \pm SE), (n=5)

Group:	Asparate amino Transferase "AST" (UL)			Alkaline phosphatase "AP" (UL)			Blood urea nitrogen (mg/dl)			Uric acid (mg/dl)		
	Time post treatment			Time post infection			Time post Infection			Time post infection		
	3 rd day	7 th day	21 st day	3 rd days	7 th days	21 st days	3 rd days	7 th days	21 st days	3 rd days	7 th days	21 st days
Non-infected, non-treated	11.54 \pm 2.36	11.22 \pm 1.8	11.98 \pm 2.41	30.4 \pm 1.8	27.6 \pm 1.2	29.4 \pm 2.3	18.2 \pm 1.5	14.78 \pm 1.1	11.3 \pm 0.55	4.68 \pm 0.21	4.8 \pm 0.32	4.6 \pm 0.21
Infected, non-treated	25.61 \pm 2.7	28.6 ^{**} \pm 3.1	35.2 ^{***} \pm 2.8	37.4 ^{**} \pm 2.1	34.6 [*] \pm 1.7	35.8 [*] \pm 2.3	29.2 \pm 0.2	24.2 ^{***} \pm 1.65	12.1 \pm 0.12	5.9 [*] \pm 0.81	7.4 ^{***} \pm 0.27	5.2 \pm 1.1
Infected, treated with Ca fosfomycin for 3 successive days	24.81 \pm 1.67	29.17 \pm 2.1	34.88 \pm 2.8	31.6 \pm 1.88	29.55 \pm 1.42	30.66 \pm 2.23	27.2 \pm 1.16	19.46 ^{**} \pm 1.8	11.87 \pm 1.64	5.1 \pm 0.22	5.5 [*] \pm 0.25	5.2 \pm 0.91
Infected, treated with Ca fosfomycin for successive 5 days	25.31 \pm 2.1	30.81 \pm 2.7	35.87 \pm	30.91 \pm 1.96	31.4 ^{***} \pm 1.4	29.78 \pm 2.41	26.99 \pm 2.41	18.82 \pm 1.8	10.77 \pm 0.55	5.1 \pm 0.66	5.4 [*] \pm 0.17	4.98 \pm 1.2

* P > 0.05

** P > 0.01

*** P > 0.001

REFERENCES

- Ali, A. R. and Youssef, E. (2003)** : Bacteriological studies and biochemical parameters of respiratory infection in Ostriches. *Vet. Med. J., Giza*, 51 (2): 189-203.
- Amani Abdlla (1993)** : Clinico-pathological studies on the effect of some antibiotic used in chickens. Ph.D. Thesis (Clinical Pathology) Fac. Vet. Med., Zagazig University.
- Awaad, M. (1972)** : Studies on coli septicemia in chicks Ph.D. Thesis, Faculty of Vet. Medicine, Cairo Univ.
- Badr, Y. A. (2003)** : Evaluation of both drugs and preventive methods used for protection from salmonella and E. coli infections in chickens. Ph.D. Thesis (Poultry Disease), Fac. of Vet. Med., Zagazig Univ.
- Baker, F. J.; Breach, M. R.; Leighton, I. and Tylor, R. (1980)** : Medical Microbiology Techniques. Bulter worth and Co. UK, London.
- Celnak, B. W.; Barnes, H. J.; Beard, C. W.; Reid, W. M. and Yoder, H. W. (1991)** : Diseases of Poultry 9th Ed., Iowa State Uni, Press Amcs. Iowa.
- Christensen, B. G.; Leanz, W. J.; Beattie, T. R.; Kuchle, F. A. and Jardtzky, O. (1969)** : Science, 166: 123-125.
- Cohen, R. R. (1967)** : Anticoagulation, centrifugation time and sample replicate number in microhematocrite method for avian blood. *Poultry Sci.*, 46: 246.
- Cruickshank, R.; Duyid, J. P. and Swain, P. H. (1976)** : Medical Microbiology 12th ed. Vol. 2. Churchill Livingstone Edinburg.
- Curtis, M. I.; Jenkins, H. G. and Butter E. J. (1970)** : The effect of E. coli endotoxin and adrenocortical hormones on plasma enzymes activity in domestic fowl. *Res. Vet. Sci.*, 28:44.
- Doumas, B. T.; Cartor, R. G. and Schaffer, R. (1981)** : Determination of serum albumin. *Clin. Chem.*, 27:1642.
- Doxey, D. L. (1971)** : Veterinary Clinical Pathology 15th Ed. London P. 556-560.
- Ferandez, A.; Lara, C.; Ramos, J.I. and Verd, M. (1998)** : Efficiency of phosphomycin in the control of E. coli infection of boiler chickens. *Res. Vet. Sci.*, 65 (3): 201-204.
- Goto, M.; Sugiyama, S. and Yamashina, H. (1981)** : Fosfomycin kinetics after intravenous and oral administration to human volunteers. *Antimicrob. Chemother.*, 20: 393-397.
- Halliwel, W. H. (1981)** : Serum chemistry profiles in healthy and disease of bird, of prey

in recent advances in the study of raptor diseases. Edited by Cooper J E. and Green Wood A.G. Chronic Publication 11d, West Yorkshire England.

Ishizawa, T. and Cole, S. (1987) : J. Pharmacol., 39: 892-895.

Laurence, D. P.; Bennett, P. N. and Brown, M. J. (1997) : Clinical Pharmacology 8th Ed. Churchill Livingstone, PP. 224.

Marches, A.; Gualco, L.; Debbia, E. A.; Schitg, G. C. and Schito, A. M. (2003) : In vitro activity of fosfomycin against gram negative urinary pathogens and the biological cost of fosfomycin resistance. Inter. J. Antimicrobial agent, 22: 553-556.

McKellar, G. A. and Verma, K. J. (1996) : Pharmacokinetics and tolerance of fosfomycin in chickens. Res. Vet. Sci. J. 28 (3): 209-213.

Natt, M. P. and Herrick, A. O. (1952) : A new blood diluent for counting the RBCs and WBCs. of chickens. Poult. Sci., 31: 735 - 738.

Perez, E. J.; Torres, M. A. and Borobio, M. V. (1977) : Synergism of fosfomycin-ampicillin and fosfomycin chloramphenicol against salmonella and shigella. Antimicrobial agent and hemotherapy, 705-709.

Reitmans, S. and Frankel, S. (1957) : A colorimetric method for determination of transaminases activity. Amer. J. Clin. Path., 28-56.

Sendecor, G. and Cochran, W. G. (1982) : Statistical Method 8th Ed. Iowa State University, Press, Ames Iowa, U.S.A.

Trinder, P. (1969) : Enzymatic colorimetric method for estimation of uric acid. Ann. Clin. Biochem., 6-24.

Weichselbaum, T. E. (1946) : An accurate and rapid method for determination of proteins in small amounts of blood serum and plasma. Am. J. Clin. Pathol. 16: 40.

منه إلى قسم العلاج ه أيام بعدة الطريقة يمكن التحكم في انتاج مضروب في شهور في الابل في
 وحالات الابل في هذه النتائج ليست في ٤٠٠ يوم /م/وزن
 ٠٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن

منه إلى قسم العلاج ه أيام بعدة الطريقة يمكن التحكم في انتاج مضروب في شهور في الابل في
 وحالات الابل في هذه النتائج ليست في ٤٠٠ يوم /م/وزن
 ٠٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن
 في كل الحشرات المصابة وغير المصابة في نفس المنطقة في الابل في ٤٠ يوم /م/وزن

مقدم بحوث صحة الضواحي بالقرينين
 صلاح محمد حسن عطية
 سامي محمد عطية

اللقاحات المستخدمة في الابل في
 الابل في